Observational studyNature communications2019
Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations.
Observational study in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06289257 (Analysis of Vitamin D and VDR Expression in Women With Advanced Endometriosis), which is not on this map. Cited by 73 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Analysis of Vitamin D and VDR Expression in Women With Advanced Endometriosis: A Case-Control Study in Thailand
Who cites it
73 citing papers in PubMed, 2 syntheses or guidelines pooled it, 131 citations in OpenAlex.
- WERF Endometriosis Phenome and Biobanking Harmonisation Project for Experimental Models in Endometriosis Research (EPHect-EM-Homologous): homologous rodent models.Molecular human reproduction · 2025Pooled it
- Adenomyosis as a Risk Factor for Myometrial or Endometrial Neoplasms-Review.International journal of environmental research and public health · 2022Pooled it
- Multi-institutional study of mesonephric-like adenocarcinoma: its clinicopathological characteristics and histogenetic association with ectopic endometrium.Virchows Archiv : an international journal of pathology · 2026Article
- The endometriosis-adenomyosis spectrum: shared pathophysiology and microenvironment-driven disease divergence.Reproductive biology and endocrinology : RB&E · 2026Review
- Building Disease Models for Endometriosis: iPSCs as Game-Changers.International journal of molecular sciences · 2026Review
- A multicenter observational study of the association between systemic immune inflammation index and adenomyosis.iScience · 2026Article
- Somatic mutations in endometrial epithelium: biological insights and emerging in vitro models.Molecular human reproduction · 2026Review
- Clinical Efficacy of Dienogest for Symptomatic Adenomyosis.Journal of clinical medicine · 2026Article
- Pathogenesis of Adenomyosis: An Integrated Review of Cellular Origins, Molecular Mechanisms, and Intersecting Diseases.Journal of cellular and molecular medicine · 2026Review
- Endometrial carcinoma risk prediction and gynecological comorbidity in adenomyosis: a 5648-case study.BMC women's health · 2026Article
- Review
- An Immunodeficient Patient with Adenomyosis of the Uterus Complicated by Polyp-Like Endometriosis: A Case Report and Review of the Literature.International journal of women's health · 2026Article
- Bioinformatic analysis and validation of candidate genes in the eutopic endometrium reveal differential expressions in diffuse adenomyosis, endometrioma, and their co-existence.European journal of medical research · 2025Article
- Efficacy and Outcomes of the Hormone-Releasing Levonorgestrel-Intrauterine System for Adenomyosis Treatment.Cureus · 2025Article
- FOXA1 expression and its association with mucin expression and KRAS mutation in ovarian mucinous tumors: implications for tumor progression and differentiation.Virchows Archiv : an international journal of pathology · 2025Article
- Progression of Follicular Thyroid Carcinomas to Anaplastic Thyroid Carcinomas: Molecular and Clinicopathologic Characteristics with Comparison to Papillary Thyroid Carcinoma-Derived Anaplastic Thyroid Carcinomas.Endocrine pathology · 2025Article
- Mutation profile and chromosomal abnormality in adenomyosis.Reproduction (Cambridge, England) · 2025Article
- Endometriosis and ovulatory menstruation: beyond the Sampson principle.The Journal of clinical investigation · 2025Review
- Prognostic factors of progesterone resistance in symptomatic adenomyosis: impact of lesion localization on treatment outcome of levonorgestrel intrauterine system.BMC women's health · 2025Article
- Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine adenomyosis is a benign disorder that often co-occurs with endometriosis and/or leiomyoma, and impairs quality of life. The genomic features of adenomyosis are unknown. Here we apply next-generation sequencing to adenomyosis (70 individuals and 192 multi-regional samples), as well as co-occurring leiomyoma and endometriosis, and find recurring KRAS mutations in 26/70 (37.1%) of adenomyosis cases. Multi-regional sequencing reveals oligoclonality in adenomyosis, with some mutations also detected in normal endometrium and/or co-occurring endometriosis. KRAS mutations are more frequent in cases of adenomyosis with co-occurring endometriosis, low progesterone receptor (PR) expression, or progestin (dienogest; DNG) pretreatment. DNG's anti-proliferative effect is diminished via epigenetic silencing of PR in immortalized cells with mutant KRAS. Our genomic analyses suggest that adenomyotic lesions frequently contain KRAS mutations that may reduce DNG efficacy, and that adenomyosis and endometriosis may share molecular etiology, explaining their co-occurrence. These findings could lead to genetically guided therapy and/or relapse risk assessment after uterine-sparing surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.